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Fabry diseaseFabry Disease (FD) is an X-linked multisystemic lysosomal disorder caused by mutations of α-galactosidase
(GLA) gene. Only a few of the 450 genetic lesions identiﬁed so far have been characterised by in vitro
expression studies. Thus the signiﬁcance of newly identiﬁed GLA nucleotide variants in FD patients which
lead to α-galactosidase (GAL-A) amino acid substitutions or intronic changes can be uncertain. We identiﬁed
three GLA mutations, c.155GNA (p.C52Y), c.548GNC (p.G183A), c.647ANG (p.Y216C) in as many individuals
(two male; one female) and performed in vitro expression studies and Western blot analysis in order to
clarify their functional effects. Reduced GAL-A activity and normal or partially reduced mutant proteins were
present in all overexpressed mutant systems in which three-dimensional structural analysis showed that the
active site was not directly involved. We hypothesize that the three new mutations affect the GAL-A protein,
leading to conformational FD. When mutant proteins overexpressed in COS-1 cells and in patients'
lymphocytes were tested in the presence of the 1-deoxygalactonojirimicin (DGJ) chaperone, the p.G183A
and p.Y216C systems showed increased GAL-A enzyme activities and protein stabilisation while p.C52Y was
not responsive. We underline that genetic, biochemical and functional studies are helpful in clarifying the
consequences of the missense genetic lesions detected in FD. ERT is the elective therapy for Fabry patients,
but it is not always possible to issue the enzyme's active form in all involved organs. Our study endorses the
hypothesis that an active site-speciﬁc chemical chaperone, which could be administered orally, might be
effective in treating GAL-A conformational defects.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Fabry disease (FD) (MIM 301500) is an X-linked recessive
lysosomal storage disorder of glycosphingolipid catabolism caused
by deﬁcient α-galactosidase A (GAL-A, E.C. 3.2.1.22) activity with a
progressive accumulation primarily of globotriaosylceramide and
related glycosphingolipids in the plasma and in the lysosomes of cells
throughout the body [1].
Angiokeratoma, acroparesthesias, hypohidrosis, renal, cardiac and
cerebrovascular involvement, and corneal opacities are the major
clinical manifestations in patients with the classic phenotype. The
onset of disease manifestations occurs in childhood or adolescence
and, if untreated, can lead to death within fourth or ﬁfth decade of life.+39 055 5662849.
.
ll rights reserved.In classically affected males the GAL-A activity can be very low or
undetectable, while patients with residual GAL-A activity can have a
milder FD phenotype [1–3].
Heterozygous female patients exhibit a spectrum of clinical
manifestations and severity from asymptomatic to severe impairment
likewise the male phenotype [4].
The human GAL-A gene (GLA), mapped on Xq22, is organized in
seven exons encompassing over 12 Kb [5]. The GLA cDNA of 1290 bp
encodes for a precursor protein of ∼50 kDa (429 amino acids), which
is proteolytically cleaved into the lysosomal mature protein [6,7]. The
mature GAL-A enzyme is a homodimeric glycoprotein of about 46 kDa
(398 amino acids), each monomer composed of two domains, a (α/
β)8 barrel domain containing the active site (encompassing amino
acids 32-330) and a C-terminal domain [8].
More than 450 mutations, scattered throughout all exons have
been reported, about 60% of which are missense, mostly private
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uk/) [9,10]. The structure of human GAL-A has been determined by X-
ray crystallographic methods [8] and the amino acid substitutions
responsible for the biochemical defect have been characterized.
Expression and functional studies on GAL-A aim to deﬁne the
mutations effects on the mature protein in order to determine
causative mutations and evaluate therapy options. Currently enzyme
replacement therapy (ERT) is the only approved treatment, but its
success is disease progression related, i.e., limited when patients have
already developed severe cardiac or renal involvement. Also, Gb3 is
proved not to be efﬁciently removed from podocytes and blood vessel
walls, and as occurs in all intravenous drug administration, ERT can
give rise to immunoreactions [11,12]. There is also a new therapeutic
approach using small molecules termed active-site-speciﬁc chaper-
ones (ASSC) which help the inﬂux of otherwise degraded misfolded
proteins into the lysosomes [12,15].
It has been reported that some missense mutations are more
responsive to chaperone 1-deoxygalactonojirimycin (DGJ) than
others. It appears that this variability is possibly connected to both
the position of the mutations and the nucleotide substitution that
leads to a different amino acid, even within one codon [15,16].
Here we report biochemical, genetic and cellular studies on three
FD patients in whom we identiﬁed two new and one known but
functionally uncharacterised GLA mutations. In order to evaluate the
inﬂuence of these mutations on the structure and activity of the
protein, we performed transient expression andWestern blot analysis
on novel missense mutations. To complete our results we tested the
therapeutic effects of DGJ and galactose on these expression systems
and that of DGJ alone on patients' leukocytes.
2. Methods
2.1. Patients
We report the clinical, biochemical and molecular studies of three
unrelated Italian patients with Fabry disease (two males and one
female). The male patients exhibited classic phenotypes, with renal
and cardiac involvement. All patients are being treated with ERT
(dosage: 1mg/kg b.w. per 1 day every 15 days for agalsidase beta, and
0.2 mg/kg/b.w. every 15 days for agalsidase alpha).
Patient 1 (P1, genotype c.155GNA, p.C52Y) is a classic Fabry
male patient and his clinical features have been summarised in a
previous report [Patient 22 in [17]]. He has presented the typical
symptoms of Fabry disease since adolescence: achroparhesthesia,
hypohydrosis, intolerance of cold, fever attacks and recurrent
abdominal pain. From the age of 27–41 years he had eight acute
episodes of cerebrovascular ischemia with a diagnosis of cerebral
vasculitis. The neurological clinical picture was progressive: at
29 years of age he presented with hemyplegia with dysartria and
onset of dyplopia that acutely worsened at 33 years; at 36 he
developed hemyanopsia on the left side and acute worsening of
right hemyplegia necessitating a cane for walking; at 41 mild acute
left hemyplegia occurred. Brain MRI performed at 42 years showed
multiple small lesions in bilateral pontocerebellar, left mesence-
phalic, posterior thalamic, lenticular nucleus, right peritrigonal and
bilateral periventricular white matter. When the patient was
42 years of age, the diagnosis of FD was made. He also had proteinuria
(552 mg/4 h), moderate hypertrophic cardiomyopathy, and bilateral
neurosensory hypoacusia. He started ERT with agalsidase alpha at the
age of 41 years and 8 months. After 5 months he had a new acute
ischemic vertebral–basilar episode. After that he began to need a
wheelchair and his dysartria worsened presenting a very reduced
personal autonomy. When last seen, in 2008, renal and heart function
had not worsened. Proteinuria was stable around 500 mg/24 h and
plasma creatinine was 0.8 mg/dl. Left ventricular mass had passed
from 170.5 to 138.4 g/m2.The female patient (P2, genotype: heterozygous for c.548GNC,
p.G183A) is 54 years old (age at diagnosis 49 years)with awide clinical
presentation of FD. She hadmild hypertension and renal involvement;
her mother underwent dialysis for several years because of renal
failure. Classic symptoms such as fever pain, acroparesthesia, and
angiokeratomawere absent. Before ERT was started at 51 years of age,
she presented podocytes damage with “zebra bodies,” proteinuria
(250 mg/h), very mild mitralic insufﬁciency, and a developing
diabetes mellitus type 2. ERT with agalsidase beta was initiated in
order to prevent the development of the disease, and in particular to
reduce renal damage, also considering diabetes mellitus and hyper-
tension as independent risk factors of cardiovascular disease and end
stage renal disease. Despite ERT, albuminuria and proteinuria remain
unchanged, even if the concentration of “zebra bodies” has decreased.
Also, themildmitralic valve insufﬁciency disappeared after 30months
of therapy.
Patient 3 (P3, genotype c.647ANG, p.Y216C) is a 56-year classic
Fabry male patient, diagnosed at 20 years of age. He presented with
diffuse angiokeratoma, acroparesthesia, pain and limb edema. Before
starting ERT, at 54 years of age, he also presented cornea verticillata,
tinnitus, vertigo and mild left ventricular hypertrophy. After starting
ERT with agalsidase alpha, acroparesthesia and fever pain crises
disappeared, but proteinuria severely worsened from 300 mg/h to
2.5 g/h. He is currently treated with Triatec 2.5mg/day and proteinuria
decreased to b500 mg/h. Heart involvement remains unchanged.
2.2. Analysis of genomic DNA
Genomic DNAs from patients and their relatives were isolated
from leukocytes. 200 ng of genomic DNA were ampliﬁed with GLA
speciﬁc oligonucleotide primers. The sequences of genomic primers
and the amplifying conditions used to amplify exons 1–7 of GLA gene
had been previously reported [18].
PCR products were checked on a 2% agarose gel, excised and
puriﬁed using Nucleospin Extraction kit (Macherey-Nagel). Approx-
imately 100 ng of puriﬁed fragments were used in sequencing
reactions. The sequencing reactions were performed using Big Dye
Terminator Cycle Sequencing Ready Reaction Kit reagents (Applied
Biosystems). The reactions were run on an ABI 310 sequencer (PE
Biosystems) and were analyzed using Sequencing Analysis Software,
version 3.3.
2.3. Restriction-site analysis
The known p.C52Y (c.155GNA) and the new p.G183A (c.548GNC)
and p.Y216C (c.647ANG) amino acid substitutions were conﬁrmed in
patients and in their relatives. A possible polymorphism effect was
excluded by testing by restriction analysis 200 control alleles for each
mutation. The restriction enzymes used were the following: Bsp1407I
for p.C52Y (c.155GNA), AluI for p.G183A (c.548GNC) and Bsp1407I
for p.Y216C (c.647ANG). All mutated fragments showed a natural
restriction site. 6 μl of PCR product were incubated for 1 h at the
temperature recommended by themanufacturer's instructions, with a
reactionmixture containing 1.5 μl of 10×reaction buffer (BM) and 5 U
of speciﬁc restriction enzyme. The total volume was brought up to
15 μl.
2.4. Mapping mutations onto structure of GAL-A
To predict the structural effect of the novel missense mutations on
resulting GAL-A enzymes we modeled the mutations onto the three-
dimensional structure of GAL-A determined by X-ray crystallography.
Amino acid substitutions corresponding to the three mutant proteins
were introduced into the wild type structure in the molecular
graphics program O. Amino acid side chain rotamers for the
substitutions were chosen to minimise steric clashes. The resulting
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minimised in the program CNS. Molecular ﬁgures were prepared
with the program Molscript.
2.5. WT GLA vector preparation
The GLA cDNA obtained was used as the PCR template. The
forward and the reverse primers were designed to introduce a
restriction site for speciﬁc endonuclease (XbaI and EcoRI). The
ampliﬁcation reactions were performed in a total volume of 50 μl
containing 2.5 U of Expand High ﬁdelity Taq polymerase (Roche),
25 mM of dNTPs, 200 ng of forward (5′CTCTAGAATGCAGCTGAG-
GAA3′) and reverse (5′CCGAATTCTTAAAGTAAGTCTTTTAA3′) primers
and 1 PCR reaction buffer. Cycle conditions were 94 °C for 2 min, 28
cycles 94 °C 15 s, 55 °C 30 s and 68 °C 2 min, with a 10-min 68 °C ﬁnal
extension cycle.
2.6. Site directed mutagenesis
Fragment replacement was used to introduce the full length GLA
cDNA in transient expression vectors, derived from pCD-X vector
kindly provided by Dr. D'azzo, St. Jude, Memphis.
The pCD-X expression vector and the full-length GLA cDNA were
cut with endonucleases XbaI and EcoRI that recognised respectively a
unique restriction site. The digested fragments were linked by a ligase
(TaKaRa Bio Inc., Japan). In the ﬁnal construct the integrity of the DNA
and the presence of only the expected GLA cDNA insert were veriﬁed
by sequencing. This expression vector was used to transform the E.
coli strain Solo pack gold cells (Stratagene, Amsterdam Zuidoost, the
Netherlands), obtaining a great quantity of vector. Plasmid DNAswere
puriﬁed by Perfectprep Plasmid Maxi kit (Eppendorf, Hamburg,
Germany).
To introduce the genetic lesions detected in the patients in the
transient expression vector, the pCD-GLA was ampliﬁed by PCR with
speciﬁc mutated oligonucleotides primers (Table 1) and the mutated
constructs were veriﬁed by sequencing. These mutated transient
expression vectors were used to transform the E. coli strain Solo pack
gold cells (Stratagene, Milan, Italy).
2.7. Transfection into COS-1 cells
Normal and mutant vectors were transiently overexpressed into
African green monkey kidney cells (COS-1). Transfection of COS-1
cells was mediated by DEAE-dextran [19]. The amount of vector used
for each transfection was about 4 μg/ml. The efﬁciency of transfection
was increased by treatment with cloroquine 100 μM (SIGMA, Milan,
Italy).
2.8. Cell cultures and biochemical enzymatic assay
COS-1 cells were cultured in Dulbecco's modiﬁed Eagles-Hams F10
medium (1:1 vol/vol) with fetal bovine serum (10%) and antibiotics.
Primary cultures of T-lymphocytes were cultured as previously
reported [12]. GAL-A enzyme assays were performed in triplicate by
ﬂuorogenic method previously reported [20] with the following
modiﬁcations: 1 mg/ml cell lysates (diluted in 10 μl of heat
inactivated 0.2% BSA+ 0.02% Na Azide) were added to 20 μl substrateTable 1
Mutated oligonucleotides for site direct mutagenesis.
Patient Nucleotide change Forward prime
P1 c.155GNA 5′ GCGCTTCAT
P2 c.548GNC 5′TGGCAGATG
P3 c.647ANG 5′CAAAAGCCCA
Underlined base correspond to the mispairings with the normal GLA sequence used to intr(4-MU-a-D-galactopyranoside 5 mM in 0.1 M Na-acetate buffer, pH
4.5 + 150 mM N-acetyl-D-galactosamine and 0.02% Na Azide); stop
solution: 200 μL of 0.5 M Na–HCO3–Na2Co3 buffer, pH 10.7 + 0.025%
Triton X-100. The Micro BCA protein Assay kit (Pierce Rockford, USA)
was used to set up the starting proteins used in each enzyme assay
performed in black 96-well microplates. Fluorescence was read on a
Spectra Max M2 microplate Reader (Molecular Devices, Toronto,
Canada).
2.9. Western blot analysis
Transfected COS-1 cells were harvested by trypsin and lysed by
sonication (10 s). 10 μg of total COS-1 cells were used in the blots. For
analytical purposes, Western blots were prepared from 12.5%
polyacrylamide gels and probed as previously described [21].
Following electrophoresis, proteins were transferred onto nitrocellu-
lose (Bio-Rad, Hercules, CA) and the ﬁlters were incubated with the
anti GAL-A antibody provided by Genzyme Corporation. The results of
the blots were visualised by reaction with the secondary antibody
anti-rabbit IgG (whole molecule) alkaline phosphatase conjugate
(SIGMA, Milan, Italy), revealed by AP Conjugate Substrate kit (Bio-
Rad, Hercules, CA).
2.10. In vitro pharmacological administration
The effects of DGJ were tested on both COS-1 cells transfected with
p.C52Y, p.G183A, p.Y216C mutated vectors and on patients' lympho-
cytes. COS-1 cells were incubated in supplemented medium with and
without DGJ 20 μM [12,16] andwith andwithout galactose 200mM as
previously reported [22]. DGJ 20 μM was administrated in patients'
lymphocyte cultures for 72 h. For the p.C52Y expression system, three
different concentrations of DGJ were used (1, 20 and 100 μM) and
incubation was followed by a washout period as previously reported
[20]. After 48 h the cells were harvested by trypsin and were tested in
triplicate by GAL-A enzyme assay.
2.11. Statistical analysis
In each experiment the value of GLA activity in non transfected
COS-1 cells was used to set up the GAL-A intrinsic activity of the
expression systems.
3. Results
3.1. Clinical and biochemical features
In the three patients reported herein the diagnosis of FD was
conﬁrmed by demonstrating the reduction or absence of GAL-A
enzyme activity in leukocytes and by molecular analysis. The highest
GAL-A activity (46% of mean control values) was detected in the
female patient (P2), and lymphocytes from P1 and P3 showed
respectively 4% and 2.5% of control activity. After starting ERT, no
improvement was observed in P1's condition. However, he has had no
more ischemic attacks and kidney and heart functions have not
worsened and ERT may have played a role in this stabilization. The
concentration of “zebra bodies” in P2's podocytes and her very mild
mitralic valve insufﬁciency disappeared after 30 months of ERT.r Reverse primer
GTACAACCTTGAC 3′ 5′ GCTAAGGTTGTACATGAAGCGC 3′
CTTATAAGCACATG3′ 5′ CATGTGCTTATAAGCATCTGCCAA 3′
ATTGTACAGAAATC 3′ 5′ GATTTCTGTACAATTGGGCTTTTG 3′
oduce the patients' mutations in the pCD-GLA vectors.
Fig. 1. GAL-A three-dimensional structural map of the three novel amino acid
substitutions.
Fig. 3. GAL-A activity resulting from DGJ and galactose administration in transfected
COS-1 cells and from DGJ administration in lymphocytes. Three independent
experiments performed in triplicate both for DGJ (20 μM) and galactose (200 mM)
administration in COS-1 transfections and for DGJ (20 μM) administration in
lymphocytes were performed. In the expression systems the value of GAL-A activity
of non-transfected COS-1 cells was used to set up the GAL-A intrinsic activity in each
experiment. Standard deviation was obtained using Microsoft Excel 97 SR-2. Values are
expressed as the percentage of wild type lymphocytes for the DGJ administration in
patients' lymphocytes and as the percentage of COS-1 cells transfected with wild type
GAL-A for the expression systems. T-lymphocytes arise from primary cultures and they
were not immortalized.
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patients was not signiﬁcantly changed after treatment. In addition, P3
has developed severe renal involvement as a new symptom.
3.2. Molecular and tridimensional data
We identiﬁed the putative disease-causing mutations of the
patients' GAL-A enzyme in three novel amino acid substitutions:
p.C52Y (c.155GNA), p.G183A (c.548GNC), p.Y216C (c.647ANG). A
polymorphic effect of such mutations was excluded by restriction
enzyme analysis of 200 control alleles. Molecular analysis extended
to other family members led to the identiﬁcation of two additional
heterozygous females, who subsequently underwent ERT.
The effect of the novel mutations on the GAL-A structure was
predicted by three-dimensional structural analyses of the mutated
enzymes (Fig. 1). All the analyzed mutations, mapping near the active
site, appear to impair protein function.
The amino acid substitutions were inserted into the pCD-GAL-A
vector by site directed mutagenesis and transiently expressed in COS-
1 cells to evaluate their in vitro activity with respect to the wild type
expression vector. Immunoblot analysis was performed to evaluate
the GAL-A stability obtained in the expression systems (Fig. 2).Fig. 2.Western blot analyses of lysates from COS-1 cells transfected with wild type and
mutant constructs. 10 μg of total proteins were used in the blots. Western blot were
carried out with the anti GAL-A antibody kindly provided by Genzyme Corporation.
Mock. Negative controls. B-Actin is reported as a control protein. Where not indicated,
DGJ concentration is 20 μM.Reduced (p.G183A and p.Y216C) or quite normal (p.C52Y) amounts of
GAL-A proteins were detected in all transfected COS-1 cells. These
results show that the p.C52Y mutated enzyme is normally expressed,
while p.G183A and p.Y216C mutations partially affect enzyme
stability and protein folding. The addition of DGJ (1 μM, 20 μM and
100 μM) to p.C52Y system resulted in no difference from the
untreated corresponding line. Interestingly, in both p.G183A and
p.Y216C systems, the GAL-A enzyme amount clearly increased, in
particular for the p.G183A system (Fig. 2).
3.3 In vitro supplementation with DGJ and galactose
Taking into account molecular and tridimensional data, expression
studies and Western blots analysis, the deleterious effects of the
analysed mutations appear to affect enzyme activity or folding.
Assuming a potential role of the mutations as conformational defects,
we tested the effects of the pharmacological chaperone DGJ at
subinhibitory concentrations (20 μM) [12] on in vitro expression
systems. To provide a positive control, we also tested the effects of
galactose at 200 mM [22].
In p.G183A and p.Y216C in vitro systems, DGJ administration
increased residual GAL-A activity. p.Y216C was more responsive to
DGJ than to galactose, and p.G183A was not inﬂuenced by galactose.
No signiﬁcant variation on residual GAL-A activity in the presence of
either pharmacological chaperones was detected in the p.C52Y
system (Fig. 3), despite three different concentrations of DGJ being
used. DGJ treatment tested on lymphocytes of patients and controls
conﬁrmed the data obtained from the experiment on p.C52Y, p.G183A
and p.Y216C expression systems (Fig. 3).
4. Discussion
The clinical onset and disease course of Fabry patients are difﬁcult
to trace. Clinical signs and symptoms are multisystemic and
nonspeciﬁc, and they may mimic other disorders such as rheumatoid
diseases or fevers. Diagnosis in male patients is made by an enzymatic
assay measuring GAL-A activity. The detection of residual GAL-A
enzyme activity could complicate a diagnosis, both in females and in
males. It has been reported that higher residual enzyme activities can
lead to milder phenotype [9].
To better deﬁne genotype–phenotype correlations, we carried out
molecular and biochemical analyses. These procedures can also be
used to identify the ‘at risk’ family members. Out of the 450 genetic
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the active site or the protein structure. Orally administrable drugs
such as small molecules acting as chaperones (ASSC) seem to be
useful in helping misfolded enzymes to reach the lysosomes [13–15].
Data in this study contribute to Fabry mutation database with two
new missense mutations p.G183A (c.548GNC), p.Y216C (c.647ANG)
conﬁrming GLA molecular heterogeneity in Fabry disease. All three
missense mutations were further analysed in Western blots, expres-
sion studies, three-dimensional structure, and ASSC administration.
Each mutation inﬂuenced the protein structure in different ways,
from changes in polarity to side chain volume. It is therefore
important to assess nucleotide substitutions individually [16]. All
three mutations here reported map in the (β/α)8 barrel domain
containing the active site but do not directly affect the amino acids
involved in the catalytic site.
The p.C52Y missense mutation, identiﬁed in P1, abolishes a
required disulﬁde bound near the active site. The disulﬁde bond is
found near p.W47, an active site residue critical for recognition of the
terminal galactose moiety on the substrate and product. Transient
expression studies of the p.C52Y showed very low GAL-A activity in
vitro, consistent with the activity detected in patients' leukocytes. The
severe nature of this mutation was conﬁrmed by in vitro chaperone
treatment: neither DGJ (20 μM) nor galactose improved residual GAL-
A activity (Fig. 3). GAL-A enzyme activity measured in p.C52Y system
supplemented with DGJ (1 and 100 mM), also remains unchanged
compared to untreated COS-1 cells transfected with the p.C52Y
mutation (data not shown).
The p.Y216C amino acid substitution was detected in a male
patient (P3) referred from a cardiac unit. Using molecular modeling
of the mutant protein, the substitution of the p.Y216 amino acid
with a Cys makes contacts to a critical loop at the active site, the
b5–a5 loop. Perturbation of this loop by the Y216C substitution may
then partially alter the geometry of the active site. GAL-A enzyme
assay on lymphocytes revealed 2.5% activity. Chaperone adminis-
tration on the p.Y216C expression system showed a signiﬁcant
increase in GAL-A activity; in particular the effect of DGJ was
greater than that of galactose. These data were conﬁrmed on
patient's lymphocytes (Fig. 3).
For p.G183A, detected in the female patient P2, a long side chain
(Ala) replaced a shorter chain (Gly183), likely causing a conforma-
tional GAL-A change affecting enzyme folding. According to three-
dimensional modeling of the mutant, there is little room in the wild
type structure to accommodate the larger side chain in the p.G183A
substitution. This mutation proved to respond well to DGJ treatment
in vitro, while it did not respond to galactose administration. Data
from lymphocytes showed that DGJ administration moves the GAL-A
residual activity's percentage from 40% to 92%, almost completely
restoring normal enzyme activity (Fig. 3).
Although none of the three mutations showed direct effects on the
15 residues that make up the active site of the enzyme, they were all
found in the second shell of residues around the active site. Thus, local
changes in the structure of the protein due to the mutations lead to a
less stable enzyme and a loss of enzyme activity. These types of
mutations are likely to be good candidates for ASSC. We believe the
p.C52Y mutant lacks a critical disulﬁde bond very close to the active
site and the active site of the enzyme is not correctly formed; thus, it
is less efﬁciently rescued by ASSC using DGJ.
In physiological conditions, proteins with altered tertiary struc-
tures are held by molecular chaperones at an endoplasmic reticulum
(ER) level and degraded in this cellular compartment [23].
Our results on the p.C52Y mutation are in keeping with recent
studies on DGJ, in which themolecule has been proved to be unable to
reverse the enzyme defects of all missensemutations [14,16,24–25]. It
therefore likely that the p.C52Y mutation inﬂuences the GAL-A active
site, whereas p.G183A and p.Y216C are related to protein folding
alterations leading to conformational FD. Such a hypothesis wassupported by Western blot analyses that showed quite normal
amount of GAL-A in p.C52Y system, while GAL-A amounts detectable
in p.G183A and p.Y216C systems were reduced. Addition of DGJ
(20 μM) to p.G183A and p.Y216C expression systems signiﬁcantly
stabilised the protein amounts. Indeed, mutant p.C52Y GAL-A did not
show any increase in protein stabilisation despite three different
concentrations of DGJ being used (Fig. 2).
Since 2001 the only approved therapy for FD has been ERT [11] but
it has also been demonstrated that the cellular distribution of the
replacement enzyme is heterogeneous [26] and is unable to remove
the substrate (Gb3) from affected tissues [11,27]. In addition, oral
administration is an easily manageable therapy against intravenous
administration as ERT needs.
DGJ administration on P2's lymphocytes (the female proband with
the p.G183A mutation) shows a complete reversion of the enzyme
defect in vitro. It would thus appear that this patient is a good
candidate for in vivo treatment.
We believe that ASSC could become a useful therapeutic
alternative for several forms of FD caused by GAL-A conformational
defects, a combined therapy using ERT and DGJ administration could
also be tested.
It is becoming clear that different nucleotide substitutions have
different impacts on GAL-A protein conformation. We therefore
support the creation of a catalogue listing changes responding and not
responding to DGJ [16].
Expression studies and structural analyses which clarify the nature
of the amino acid lesions involved in FD are essential to improve
therapeutic approaches available for the disease. As response to DGJ
administration is variable, each patient should be tested for new
mutations before ASCC therapy is introduced.
A phase 2 trial, using DGJ molecules called AT1001 migalastat
hydrochloride (Amigaltm) distributed by Amicus Therapeutics, has
been completed for some Fabry patients carrying responder confor-
mational mutations.
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